---
title: 'Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617
  Uptake?'
date: '2024-04-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38675472/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240427180604&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: '[^(177)Lu]Lu-PSMA-617 has recently been successfully approved by the
  FDA, the MHRA, Health Canada and the EMA as Pluvicto^(®). However, salivary gland
  (SG) and kidney toxicities account for its main dose-limiting side-effects, while
  its corresponding uptake and retention mechanisms still remain elusive. Recently,
  the presence of different ATP-binding cassette (ABC) transporters, such as human
  breast cancer resistance proteins (BCRP), multidrug resistance proteins ...'
disable_comments: true
---
[^(177)Lu]Lu-PSMA-617 has recently been successfully approved by the FDA, the MHRA, Health Canada and the EMA as Pluvicto^(®). However, salivary gland (SG) and kidney toxicities account for its main dose-limiting side-effects, while its corresponding uptake and retention mechanisms still remain elusive. Recently, the presence of different ATP-binding cassette (ABC) transporters, such as human breast cancer resistance proteins (BCRP), multidrug resistance proteins ...